SCL Science Inc. (246960.KQ) Stock
SCL Science Inc.

Company profile
SCL Science reported revenue of 22.01 billion KRW for fiscal year 2025, and a net loss of 3.93 billion KRW. That is a net profit margin of -17.9% for fiscal year 2025. Our analysis of its filings shows revenue growing from 1.32 billion KRW in fiscal year 2023 to 22.01 billion KRW in fiscal year 2025, 308.0% a year on average. SCL Science reports about 159 full-time employees.
What stands out
- Revenue more than tripled (up 364.6%) in fiscal year 2025, from 4.74 billion KRW in fiscal year 2024, after a rise of 258.3% the year before.
- It reported a net loss in each of its last 5 fiscal years (2021 to 2025).
Figures from company filings; latest fiscal year ended December 31, 2025.
About SCL Science Inc.
SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products include BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal, which is used for specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields, such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasis and sealing products; STOP, a non-bleeding intravascular injection; Film that prevents leakage at intestinal and vascular anastomosis sites; InnoLOCK and InTro vascular interventional procedure items; and operates bio-logistics business. The company also engages in conducting clinical trial analysis services related to new drug development, in vitro diagnostic medical device performance evaluation, transportation of pharmaceuticals and clinical trial samples, etc. The company was formerly known as InnoTherapy, Inc. and changed its name to SCL Science Inc. in March 2024. SCL Science Inc. was founded in 2010 and is headquartered in Seoul, South Korea.
Leadership
- Moon Sue Lee — Founder & CEO
- Chang Yeon Kim — President of InnoTherapy America, Inc.
- In Keun Moon — CFO, COO & VP
- Hae-Shin Lee — Founder & CTO, 52
- Hong Kee Kim Ph.D. — Head of Research & Development Center
How much revenue does SCL Science make?
SCL Science reported 22.01 billion KRW in revenue for fiscal year 2025, up 364.6% from 4.74 billion KRW in fiscal year 2024.
What companies are similar to SCL Science?
Listed companies of a similar size in the same industry (distribution management companies) include Eusu Holdings Co., Ltd. (000700.KS), Hansol Logistics Co., Ltd. (009180.KS), Taewoong Logistics Co., Ltd. (124560.KQ), Dongbang Transport Logistics Co., Ltd. (004140.KS).
How has SCL Science's revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, 507.29 million KRW; FY2022, 369.78 million KRW; FY2023, 1.32 billion KRW; FY2024, 4.74 billion KRW; FY2025, 22.01 billion KRW.
Has SCL Science made a profit in recent years?
Net income by fiscal year: FY2021, a loss of 5.03 billion KRW; FY2022, a loss of 5.97 billion KRW; FY2023, a loss of 5.03 billion KRW; FY2024, a loss of 3.73 billion KRW; FY2025, a loss of 3.93 billion KRW. It reported a net loss in each of these 5 years.
Company Information
Data as of .
How to cite: DataPorium, “SCL Science Inc. (246960.KQ)”, data as of Dec 31, 2025, https://dataporium.tech/stocks/246960.KQ